Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices-MedSci.cn

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

Pepin, XJH; Moir, AJ; Mann, JC; Sanderson, NJ; Barker, R; Meehan, E; Plumb, AP; Bailey, GR; Murphy, DS; Krejsa, CM; Andrew, MA; Ingallinera, TG; Slatter, JG

Pepin, XJH (reprint author), AstraZeneca, Pharmaceut Technol & Dev, Charter Way, Macclesfield SK10 2NA, Cheshire, England.

Abstract

Acalabrutinib (Calquence (R)) 100 mg (bid) has received accelerated approval by FDA for the treatment of adult patients with mantle cell lymphoma (MCL......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

科室

工具

服务